The Worldwide Non-Small Cell Lung Cancer Treatment Industry is Expected to Reach $25.7 Billion by 2027 - ResearchAndMarkets.com
Retrieved on:
Tuesday, August 16, 2022
Pharmaceutical, Health, Oncology, Smoker, Lung cancer, Cancer, Death, Sinonasal undifferentiated carcinoma, Incidence, Hospital, Patient, Cell, COVID-19, Large-cell lung carcinoma, Projection, Awareness, Adenocarcinoma, CAGR, Immunotherapy, Squamous-cell carcinoma of the lung, Squamous cell carcinoma, Asbestos, Adoption, Uranium, Pharmaceutical industry, NSCLC
The non-small cell lung cancer subtype accounts for most lung cancer cases (NSCLC).
Key Points:
- The non-small cell lung cancer subtype accounts for most lung cancer cases (NSCLC).
- As a result of the expanding frequency and incidence of non-small cell lung cancer across all demographics and age categories, demand for non-small cell lung cancer therapies has increased.
- Non-Small Cell Lung Cancer Treatment (NSCLC) Market represented a central challenge in clinical diagnosis and therapy decision-making in the context of the favorably contagious COVID-19 pandemic.
- The rise of the non-small cell lung cancer therapy (NSCLC) market has been fuelled by the increased number of non-small cell lung cancer diagnoses and increased awareness in developed and emerging countries.